INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors


Study Number
73818
Phase
1
Purpose

The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.

Full Title

A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors (POD1UM-102)

ClinicalTrials.Gov ID
NCT03589651

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.